Update on the management of polycystic ovary syndrome.
Journal Title: Pharmacological Reports - Year 2006, Vol 58, Issue 5
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5% to 10% of women in reproductive age. It is the most simply defined as the association of hyperandrogenism (diagnosed clinically and/or biochemically) with chronic anovulation in the absence of specific ovarian, adrenal and pituitary gland diseases. Recent studies have revealed that PCOS is associated with hyperinsulinemia and insulin resistance. Both of them have been shown to play a substantial role in the increased risk of the cardiovascular events. The new data concerning the pathogenesis and management of PCOS have changed its treatment strategy. The management of PCOS is complex and includes lifestyle modification combined with dietary-induced weight loss, oral contraceptives, clomiphene citrate, gonadotropins, antiandrogens and insulin-sensitizing agents. Women with PCOS, diagnosed and managed properly, can benefit from the reduction or even reversal of the reproductive and metabolic morbidities and from the reduction of the risk factors for cardiovascular disorders. In this article, we describe all these treatment options. Although both standard and novel therapies are discussed, this review focuses on the progress made in the recent years.
Authors and Affiliations
Robert Krysiak, Bogusław Okopień, Anna Gdula-Dymek, Zbigniew Herman
Keywords
Related Articles
- EP ID EP133912
- DOI -
- Views 106
- Downloads 0
In vivo effects of high-dose methotrexate on bone remodeling in rats.
Methotrexatae (MTX) is a folate antagonist. MTX osteopathy is well recognized to accompany a high-dose therapy with this drug for the treatment of childhood malignancy. Clinical tests also show that low-dose MTXused in t...
Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight.
TP-7 is a synthetic analogue of tuftsin. It has a structure of tuftsin, to which three natural L-amino-acids Pro-Gly-Pro are attached. This heptapeptide improves learning and memorization and causes antidepressant and an...
Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice.
Background: Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve treatment of the negative and certain cognitive symptoms of schizophrenia. Met...
Synthesis and pharmacological properties of new GABA uptake inhibitors.
Background: γ-Aminobutanoic acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system. The identification and subsequent development of the GABA transport inhibitors which enhance t...
Editorial.